Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7968286: Settings for recombinant adenoviral-based vaccines

Share

Filing Information

Inventor(s) Menzo J. E. Havenga · Stefan Kostense ·
Assignee(s) Crucell Holland B.V. ·
Attorney/Agent(s) TraskBritt ·
Primary Examiner Bo Peng ·
Application Number US12930661
Filing date 01/12/2011
Issue date 06/28/2011
Prior Publication Data
Predicted expiration date 10/23/2023
U.S. Classifications 435/5  · 435/8  ·
International Classifications C12Q166  · C12Q170  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 11/978,043, filed Oct. 25, 2007, now abandoned, which application is a divisional of U.S. patent application Ser. No. 11/105,725, filed Apr. 14, 2005, now U.S. Pat. No. 7,598,078issued Oct. 6, 2009, which is a continuation of International Patent Application No. PCT/EP03/050748, filed on Oct. 23, 2003, designating the United States of America, and published, in English, as PCT International Publication No. WO 2004/037294 A2 on May 6, 2004, which claims priority under Article 8 of the PCT to International Patent Application No. PCT NL02/00671, filed Oct. 23, 2002, the entire disclosure of each of which is incorporated herein by this reference.
Foreign Priority NLPCTNL0200671 - 10/23/2002 ·
8 Claims, 37 Drawings


Abstract

Described are of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, described are assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Independent Claims | See all claims (8)

  1. 1. A method for determining a titer of neutralizing antibodies directed against adenoviruses in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of the human or animal; culturing host cells which can be infected with a recombinant adenovirus; admixing the serum sample, the host cell culture and the recombinant adenovirus, wherein the recombinant adenovirus comprises a transgene encoding luciferase; incubating the admixture for about 24 hours; determining the activity of luciferase in the admixture; and comparing the activity of luciferase in the admixture to a serum-free control, thereby determining the titer of neutralizing antibodies in the blood sample; wherein the titer of neutralizing antibodies is determinable with 1000 host cells.
  2. 7. A high-throughput method for determining a titer of neutralizing antibodies directed against adenoviruses in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of said human or animal; culturing host cells which can be infected with a recombinant adenovirus; admixing the serum sample, the host cell culture and recombinant adenovirus, wherein the recombinant adenovirus comprises a transgene encoding luciferase; incubating the admixture for about 24 hours; determining the activity of luciferase in the admixture; and comparing the activity of luciferase in the admixture to a serum-free control, thereby determining the titer of neutralizing antibodies in the serum sample; wherein 1000 host cells are sufficient to determine the titer of neutralizing antibodies.
  3. 8. A method for determining the relative titers of neutralizing antibodies directed against adenoviruses of different serotypes in a human- or animal-derived blood sample, the method comprising: obtaining a serum sample of said human or animal; providing cultured host cells which can be infected by recombinant adenovirus of a first serotype and a second serotype; admixing a first portion of the serum sample, a first portion of the cultured host cells and a recombinant adenovirus of the first serotype to form a first admixture, wherein the recombinant adenovirus of the first serotype comprises a transgene encoding luciferase; admixing a second portion of the serum sample, a second portion of the cultured host cells and a recombinant adenovirus of the second serotype to form a second admixture, wherein the recombinant adenovirus of the second serotype comprises a transgene encoding luciferase; incubating the admixtures for about 24 hours; determining the activity of luciferase in both the first and second admixtures; and comparing the luciferase activities in the first and second admixtures to a serum-free control, thereby determining the relative titers of neutralizing antibodies to adenoviruses of the first and second serotypes in the serum sample; wherein 1000 host cells will provide a titer of neutralizing antibodies.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US5922315 Genetic Therapy, Inc. Roy Jul 1999
US5994128 IntroGene B.V. Fallaux et al. Nov 1999
US6492169 Crucell Holland, B.V. Vogels et al. Dec 2002
US6670188 Crucell Holland B.V. Vogels et al. Dec 2003
US6733993 Merck & Co., Inc. Emini et al. May 2004
US6913922 Crucell Holland B.V. Bout et al. Jul 2005
US20030044421 Emini et al. Mar 2003

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP99201545.3May 1999
EP0978566Crucell Holland B.V.Feb 2000
WO199626281Aug 1996
WO199832842Jul 1998
WO199850053Nov 1998
WO199964582INTROGENE B.V.Dec 1999
WO200003029INTROGENE B.V.Jan 2000
WO200052186INTROGENE B.V.Sep 2000
WO200060106MERCK & CO., INC.Oct 2000
WO200070071INTROGENE B.V.Nov 2000
WO200102607MERCK & CO., INC.Jan 2001
WO200121201ISIS INNOVATION LIMITEDMar 2001
WO200222080MERCK & CO., INC.Mar 2002
WO200224730CRUCELL HOLLAND B.V.Mar 2002
WO2002053759Jul 2002
WO2004028478MEDIMMUNE VACCINES, INC.Apr 2004

Other Publications

Anderson, et al.; A simple method for the rapid generation of recombinant adenovirus vectors; Gene Ther., Jun. 8, 2000; 7 (12); pp. 1034-1038.
Basler. et al.; Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35, Gene, 1996 pp. 249-254, vol. 170.
Bostic. et al., Quantitative Analysis of Neutralizing Immune Response to Human Parvovirus BI9 Using a Novel Reverse Transcriptase-Polymerase Chain Reaction-Based Assay, Journal of Infectious Disease, 1999, pp. 619-626, vol. 179, Chicago, IL, US.
European Search Report, EP 03 780 172, dated Dec. 6, 2007.
Flomenberg, et al.; Sequence and genetic Organization of Adenovirus Type 35 Early Region 3; Journal of Virology. Nov. 1988, pp. 4431-4437, vol. 62, No. 11.
Flomenberg, et al; Molecular Epidemiololgy of Adenovirus Type 35 Infections in Immunocompromised Hosts; The Journal of Infectious Diseases, Jun. 1987, pp. 1127-1134, vol. 155, No. 6.
Gaher Y-Segard, et al.; Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have Synergistic Effect on Neutralizing Activity; Journal of Virology. Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Hsu, et al., Immunogenicity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenovirus Types 4, 5, and 7 Vectors in Dogs and a chimpanzee; Journal of Infectious Diseases, Oct. 1, 1992, pp. 769-775, vol. 166, No. 4.
Kang, et al.; Molecular Cloning and Physical Mapping of the DNA of Human Adenovirus Type 35, Acta Microbiologica Hungarica 1999, pp. 67-75, vol. 36, No. 1.
Kass-Eisler. et al.: Circumventing the immune response to adenovirus-mediated gene therapy; Gene Therapy, Feb. 1, 1996, pp. 154-162, vol. 2. No. 3.
Klein, et al.; Accurate estimation of transduction efficiency necessitates a multiplex real-time PCT, Gene Therapy, 2000, pp. 458-463, vol. 7.
Krasnykh, et al.; Generation of Recombinant Adenovirus Vectors with modified Fibers for Altering Viral Tropism. Journal of Virology. Oct. 1996. pp. 6839-6846, vol. 70. No. 10.
Liu, et al., Is Green Fluorescent Protein Toxic to the Living Cells? Biochemical and Biophysical Research Communication, 1999. pp. 712-717, vol. 260.
Lubeck, et al., Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus, Proc. Natl. Acad. Sci. USA, 1989, pp. 6763-6767, vol. 86, No. 17.
Mack, et al.; Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype; Human Gene Therapy, 1997, pp. 99.109, vol. 8, No. 1.
Mastrangeli, et al., Sero-Switch Adenovirus—Mediated in Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype; Human Gene Therapy, 1996, pp. 79-87, vol. 7, No, 1.
Moffatt, et al.; Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non Human Adenoviruses: Implications in Gene Therapy, Virology, Jun. 30, 2000, pp. 159-167, vol. 272, No. 1.
Natuk, et al.; Adenovirus Vectored Vaccines, Developments in Biological Standardization , 1994, pp. 71-77, vol. 82.
Natuk, et al.; Adenovirus-human deficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model, Proc. Natl. Acad. Sci. USA, Aug. 1992, pp. 7777-7781, vol. 89, No. 16.
Natuk, et al.; Immunogenicity of Recombinant Human Adenovirus—Human Immunodeficiency Virus Vaccines in Chimpanzees, AIDS Research and Human Retroviruses, 1993, pp. 395-404, vol. 9, No. 5.
Nishimura, et al., Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, Mar. 2002, pp. 2123-2130. vol. 76, No. 5.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Parks, et al.; Use of a helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration; Gene Therapy, Sep. 1999, pp. 1565-1573, vol. 6, No. 1.
PCT International Preliminary Examination Report, PCT/EP03/50748, dated Feb. 14, 2005.
Reynolds, et al.; A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo; Molecular Therapy, 2(6); pp. 562-578. 2000.
Rodrigues, et al.; Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria, J. Immunol., Feb. 1, 1997; pp. 1268-1274, vol. 158, No. 3.
Rosenfeld, et al.; Adenovirus-Mediated Transfer of a recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo; Science, Apr. 19, 1991; pp. 431-434, vol. 252.
Roy, et al.; Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon, Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
Schroter, et al.; Quantitative Detection of Hepatitis C Virus RNA by Light Cycler PCR and Comparison with Two Different PCR Assays, Journal of Clinical Microbiology, Feb. 2001, pp. 765-768, vol. 39. No. 2.
Shiver, et al. ; Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity, Nature, 2002. pp. 331-335. vol. 415, No. 6869.
Spenlehauer, et al.; A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type I, Virology. 2001, pp. 292-300, vol. 280.
Sprangers,et al.; Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors, Journal of Clinical Microbiology, Nov. 2003, pp. 5046-5052, vol. 41, No. 11.
Stallwood, et al.; Neutralisation of adenovirus infectivity by ascetic fluid from ovarian cancer patients: Gene Ther. Apr. 2000; 7(8): pp. 637-643.
Stevenson. et al.; Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain: Journal of Virology. May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet. et al., Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector. Human Gene Therapy, 1990, pp. 241-256, vol. 1.
Sullivan, et al.; Development of a preventive vaccine for Ebola virus infection in primates, Nature, 2000, pp. 605-609, vol. 408, No. 6812.
Taghizadeh, et al., CRF and YFP, but Not GFP, Provide Stable Fluorescent Marking of Rat Hepatic Adult Stem Cells, Journal of Biomedicine and Biotechnology, 2008, pp. 1-9, vol. 2008, Hindawi Publishing Corporation.
Tetteh, et al.; Progress and challenges towards the development of malaria vaccines, Biogruds, 2007, pp. 357-373, vol. 21, No. 6.
Vogels, et al.; Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity. Journal of Virology, Aug. 2003, pp. 8263-8271. vol. 77, No. 15.
Notice of Allowance for U.S. Appl. No. 11/105,725, dated Jun. 17, 2009.

Referenced By

Document NumberAssigneeInventorsIssue/Pub Date
US8097453 Crucell Holland B.V. Maria G. Pau et al. Jan 2012

Patent Family

The current document is not in a family.